journal article·2025-05-21Open access

From Bimetallic Oleates to Customized Biomedical Nanoplatforms: A Versatile Approach for the Multidoping of Ferrites

Daniela Iglesias-Rojas, Karam Nader, Nerea Fernández-Lavilla, Jon Mentxaka-Salgado, Izaskun Gil de Muro, José S. Garitaonandia, Iñaki Orue, Ainara Castellanos-Rubio, Maite Insausti, Idoia Castellanos-Rubio

ACS Applied Materials & Interfaces· Volume 17· Issue 20

Abstract

High Resolution Image Download MS PowerPoint Slide The present work represents a significant advancement in the design of magnetic nanoparticles for biomedical applications. Herein, an improved chemical approach is presented, involving the thermal decomposition of various Fe–M bimetallic oleates (where M = Mn, Co, and Zn). Through this method a series of nanoparticles (NPs) with moderate doping levels have been successfully synthesized, categorized into monodoped (M x Fe 3– x O 4 ) or multidoped (M A x M B y Fe 3– x – y O 4 ). This advanced synthesis technique has yielded six highly monodisperse samples composed of single nanocrystals with an octahedral-like shape and with high saturation magnetization. The uniform composition of the samples has been verified using DC magnetometry, and the dopants’ lattice occupation has been analyzed via 57 Fe-Mössbauer spectroscopy. By modeling the AC/DC hysteresis loops, the magnetic anisotropy constants at low and room temperatures have been determined. Furthermore, the biomedical potential of the PEGylated NPs has been investigated by evaluating their magnetothermal performance, magnetic targeting capability, cytotoxicity, and antitumoral therapeutic capacity in a colon cancer-derived cell line. These findings highlight the tunable nature of the synthesized nanoplatforms, enabling precise optimization of their magnetic properties for diverse nanomedicine applications. Notably, Mn-doped nanoparticles have shown efficient heating power at 15 mT, while Mn–Co-doped counterparts have achieved exceptionally high heating at 45 mT. Additionally, the Mn–Zn nanosystem has demonstrated strong potential for both magnetic targeting and magnetic hyperthermia, further underscoring the versatility of these engineered nanomaterials.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Iron oxide chemistry and applications · Nanoparticle-Based Drug Delivery · Magnetic Properties and Synthesis of Ferrites

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Dpto. Química Orgánica e Inorgánica, Facultad de Ciencia y Tecnología, UPV/EHU, Barrio Sarriena s/n, 48940 Leioa, Spain

Department of Biochemistry and Molecular Biology, UPV/EHU, Barrio Sarriena s/n, 48940 Leioa, Spain

Biocruces Bizkaia Health Research Institute

Dpto. Física, Facultad de Ciencia y Tecnología, UPV/EHU, Barrio Sarriena s/n, 48940 Leioa, Spain

SGIker, Servicios Generales de Investigación, UPV/EHU, Barrio Sarriena s/n, 48940 Leioa, Spain

Department of Genetics, Physical Anthropology and Animal Physiology

University of the Basque Country UPV/EHU

Biomedical Research Center in Diabetes Network and Associated Metabolic Diseases CIBERDEM

Instituto de Salud Carlos III

IKERBASQUE Basque Foundation for Science

BC Materials, Basque Center for Materials, Applications and Nanostructures, Barrio Sarriena s/n, 48940 Leioa, Spain

Funding

Ministry of Science, Innovation and Universities · European Commission · Eusko Jaurlaritza · Euskal Herriko Unibertsitatea · Grant from the Department of Health of the Basque Government

References (64)

Show source-provided references
1. 10.1016/j.jallcom.2017.02.02110.1016/j.jallcom.2017.02.021 ↗
2. 10.1021/acs.nanolett.9b0063010.1021/acs.nanolett.9b00630 ↗
3. 10.1021/acs.chemmater.7b0003510.1021/acs.chemmater.7b00035 ↗
4. 10.1016/j.cscee.2023.10030310.1016/j.cscee.2023.100303 ↗
5. 10.1016/j.redox.2023.10265110.1016/j.redox.2023.102651 ↗
6. 10.1016/j.jddst.2019.10128210.1016/j.jddst.2019.101282 ↗
7. 10.1021/acs.chemmater.8b0359110.1021/acs.chemmater.8b03591 ↗
8. 10.1002/adma.20200371210.1002/adma.202003712 ↗
9. 10.1021/acs.chemmater.7b0003510.1021/acs.chemmater.7b00035 ↗
10. 10.1021/acsami.2c1401610.1021/acsami.2c14016 ↗
11. 10.1038/s41598-023-28914-410.1038/s41598-023-28914-4 ↗
12. 10.1002/smll.20180013510.1002/smll.201800135 ↗
13. 10.1039/C9DT01620A10.1039/C9DT01620A ↗
14. Cullity B. D. · 1972
15. 10.1021/nn403526610.1021/nn4035266 ↗
16. 10.1021/acs.chemmater.5b0326110.1021/acs.chemmater.5b03261 ↗
17. 10.1143/PTP.23.105510.1143/PTP.23.1055 ↗
18. 10.1002/anie.20080514910.1002/anie.200805149 ↗
19. 10.1021/acs.chemmater.9b0158210.1021/acs.chemmater.9b01582 ↗
20. 10.1021/nl304115r10.1021/nl304115r ↗
21. 10.3390/ma1401010010.3390/ma14010100 ↗
22. 10.1016/j.jallcom.2017.01.29710.1016/j.jallcom.2017.01.297 ↗
23. 10.1021/acs.jpcc.9b0659910.1021/acs.jpcc.9b06599 ↗
24. 10.1016/j.jallcom.2023.16932710.1016/j.jallcom.2023.169327 ↗
25. 10.1039/c4nr00646a10.1039/c4nr00646a ↗
26. 10.1021/acs.chemmater.2c0204610.1021/acs.chemmater.2c02046 ↗
27. 10.1039/C9NR04970C10.1039/C9NR04970C ↗
28. 10.1021/acs.chemmater.1c0265410.1021/acs.chemmater.1c02654 ↗
29. 10.1002/adfm.20200057710.1002/adfm.202000577 ↗
30. 10.1021/acsnano.7b0643910.1021/acsnano.7b06439 ↗
31. 10.1021/acs.chemmater.0c0479410.1021/acs.chemmater.0c04794 ↗
32. 10.1039/D4RA01600A10.1039/D4RA01600A ↗
33. 10.1039/C2JM15228B10.1039/C2JM15228B ↗
34. 10.1016/0921-4526(93)90108-I10.1016/0921-4526(93)90108-I ↗
35. 10.1107/S002188986900655810.1107/S0021889869006558 ↗
36. 10.1107/S056773947600155110.1107/S0567739476001551 ↗
37. 10.1063/1.355158210.1063/1.3551582 ↗
38. 10.1039/D0NR02189J10.1039/D0NR02189J ↗
39. 10.1049/pi-b-1.1957.003810.1049/pi-b-1.1957.0038 ↗
40. 10.1103/PhysRev.110.134110.1103/PhysRev.110.1341 ↗
41. 10.1103/PhysRev.99.178810.1103/PhysRev.99.1788 ↗
42. 10.1021/acs.jpcc.8b0118710.1021/acs.jpcc.8b01187 ↗
43. 10.1038/144327b010.1038/144327b0 ↗
44. 10.1016/0925-8388(95)01677-510.1016/0925-8388(95)01677-5 ↗
45. 10.1103/PhysRevB.64.01240210.1103/PhysRevB.64.012402 ↗
46. 10.1063/1.497696610.1063/1.4976966 ↗
47. 10.1039/C9CC06258K10.1039/C9CC06258K ↗
48. 10.1021/acs.chemmater.2c0156810.1021/acs.chemmater.2c01568 ↗
49. 10.2138/am.2010.343510.2138/am.2010.3435 ↗
50. 10.1143/JJAP.32.79610.1143/JJAP.32.796 ↗
51. 10.1007/s10853-016-9853-310.1007/s10853-016-9853-3 ↗
52. 10.1103/PhysRevB.31.43010.1103/PhysRevB.31.430 ↗
53. 10.1021/acsami.0c0322210.1021/acsami.0c03222 ↗
54. 10.1080/02656736.2020.180207110.1080/02656736.2020.1802071 ↗
55. 10.1103/PhysRev.130.167710.1103/PhysRev.130.1677 ↗
56. 10.1088/0953-8984/18/38/S2610.1088/0953-8984/18/38/S26 ↗
57. 10.1002/adfm.20180184010.1002/adfm.201801840 ↗
58. Lübbe A. S. · Cancer Res. · 1996 · 56 · 4686
59. 10.1016/j.jconrel.2014.07.05910.1016/j.jconrel.2014.07.059 ↗
60. 10.1021/acs.nanolett.6b0226110.1021/acs.nanolett.6b02261 ↗
61. 10.1038/s41598-020-71552-310.1038/s41598-020-71552-3 ↗
62. 10.1021/acsami.0c0322210.1021/acsami.0c03222 ↗
63. 10.3390/pharmaceutics1308121910.3390/pharmaceutics13081219 ↗
64. 10.1038/s41598-022-12687-310.1038/s41598-022-12687-3 ↗